Skip to main content

Table 1 Characteristics of the randomized controlled trials assessing the effect of prior preventive treatment failures on the treatment with erenumab for migraine prevention

From: The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

  NCT02066415
[9,10,11,12,13]
STRIVE
[14,15,16]
LIBERTY
[17, 18]
Phase II III IIIb
Migraine type CM EM EM
Dose (mg) 70/140 70/140 140
OLE duration (weeks) 52 52 24
Duration of blind phase (weeks) 12 24 12
Prior preventive treatment failuresa accepted ≤3 ≤2 2–4
No. of patients
 Placebo 286 319 125
 70 mg 191 317
 140 mg 190 319 121
Patients with prior preventive treatment failure(s) (%)
 Placebo 70 40 100
 70 mg 67 40
 140 mg 66 36 100
  1. MMD Monthly Migraine Days, OLE Open-Label Extension, EM Episodic Migraine, CM Chronic Migraine
  2. adue to lack of response; partial response or suspension due to tolerability were accepted
\